SARS-CoV RBD – Communicable Diseases Research

Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19

코로나19 중증도에 따라 항체 표적 SARS-CoV-2 에피토프 레퍼토리 달라

Article

Published on 2022-12-012022-09-11
Journal: Virulence
[Category] COVID19(2023년), SARS, 진단, 치료법,

564. SARS-CoV-2 Ferritin Nanoparticle Vaccines Elicit Broad SARS Coronavirus Immunogenicity

Poster Abstracts

Published on 2021-11-042022-10-29
Journal: Open Forum Infectious Diseases
[Category] COVID-19,

[키워드] analyzed antibody antigenic approach binding breadth clinical trial Combination domain elicit elicited Emergency use authorization global pandemic Heterologous High-dose highlight immune response immunization immunogen immunogenicity K18-ACE2 K18-hACE2 mice Multiple murine mutations N-terminal domain nanoparticle neutralization Neutralizing NTD observation pandemic platform prefusion pseudovirus RBD reported responses Result robust SARS-CoV RBD SARS-CoV-1 SARS-CoV-1 RBD SARS-CoV-1 virus SARS-CoV-2 SARS-CoV-2 neutralizing antibody SARS-CoV-2 RBD SARS-CoV-2 variant SARS-CoV-2 virus SARS-CoV-2 virus variant SARS-like coronavirus sera spike the SARS-CoV-2 transfused transgenic mice Transgenic mouse Vaccine Vaccine design vaccine platform variant variants of concern virus were assessed zoonotic
[DOI] 10.1093/ofid/ofab466.762 PMC 바로가기 [Article Type] Poster Abstracts

Generation and Characterization of a Nanobody Against SARS-CoV

SARS-CoV에 대한 나노바디의 생성 및 특성화

Research Article

Published on 2021-08-172022-09-12
Journal: Virologica Sinica
[Category] MERS, SARS, 진단,

[키워드] ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus Against against SARS-CoV angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 antibody antiviral drug binding blocked caused characterization clone competitive inhibition coronavirus demonstrated domain E. coli enzyme expression Generation high affinity immunized mononuclear cell nanobodies nanobody neutralization activity neutralizing antibody outbreak Panic Peripheral blood Peripheral blood mononuclear cells positive pseudovirus RBD Receptor-binding domain (RBD) risk SARS-CoV SARS-CoV pseudovirus SARS-CoV RBD selected severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus (SARS-CoV) therapeutic therapeutic antibodies Therapeutics Vaccine
[DOI] 10.1007/s12250-021-00436-1 PMC 바로가기 [Article Type] Research Article

A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection

교차 중화 항체의 조합은 SARS-CoV-2 및 SARS-CoV 슈도바이러스 감염을 예방하기 위해 상승합니다.

Article

Published on 2021-05-122022-09-10
Journal: Cell Host & Microbe
[Category] MERS, SARS, 변종, 진단,

[키워드] 3D structure Abstract antibodies antibody antibody cocktail antibody-antigen interaction antigenic antigenic drift antigenic variation B.1.1.7 B.1.351 bind bound waters caused circulating variant circulating variants Combination complex conserved coronavirus coronavirus disease Coronavirus disease 2019 COVA1-16 COVID-19 COVID-19 patient CR3022 cross-neutralizing cross-neutralizing antibodies cross-neutralizing antibody cross-react cross-reactivity crystal structure crystal structures Crystallography Effectiveness ENhance Epidemics facilitate glycan glycosylation site Infection information interact Interaction neutralization neutralize Neutralizing antibodies Pandemics Prevent PROTECT provide receptor-binding domains Recognition related viruses S309 Sarbecoviruses SARS-CoV SARS-CoV pseudovirus SARS-CoV RBD SARS-CoV RBDs SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants SARS-related coronaviruses SARS-related virus SARS-related viruses shown spike spikes Structure synergy the receptor-binding domain therapeutic therapeutic antibodies these viruses threat Threats Vaccine viruses X-ray zoonotic
[DOI] 10.1016/j.chom.2021.04.005 PMC 바로가기 [Article Type] Article

Cell entry mechanisms of SARS-CoV-2

530

Published on 2020-05-262022-10-29
Journal: Proceedings of the National Academy of Sciences of
[Category] COVID-19, SARS,

[키워드] ACE2 receptor activated Activation acute respiratory syndrome bind binding affinity biochemical Cell cell entry cells comparable contribute coronavirus coronavirus disease COVID-19 domain Entry mechanism entry receptor feature furin hACE2 hidden highlighting human ACE2 human cell immune immune evasion Intervention investigated less maintain mechanism mechanisms pandemic proprotein convertase furin protease Proteases provide pseudovirus entry assay pseudovirus entry assays RBD receptor Receptor binding reducing SARS-CoV SARS-CoV RBD SARS-CoV-2 SARS-CoV-2 entry SARS-CoV-2 RBD SARS-CoV-2 spike second Significance Spike protein Spread Surveillance the RBD understanding virus
[DOI] 10.1073/pnas.2003138117 PMC 바로가기 [Article Type] 530

Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies

Article

Published on 2020-05-152022-11-01
Journal: Cellular and Molecular Immunology
[Category] COVID-19, SARS,

[키워드] ACE2 against SARS-CoV amino acid residue analyzed angiotensin-converting enzyme 2 antibody antigenic bind binding site block viral entry caused Coronavirus disease 2019 coronavirus SARS-CoV-2 COVID-19 COVID-19 pandemic cross-neutralizing cross-neutralizing antibody develop drug epitope F486 feature host receptor human ACE2 Humoral immunity immunization in vivo experiment indicate induce Infection mechanism neutralize Neutralizing antibodies neutralizing antibody neutralizing monoclonal antibody Prophylactic public health RBD receptor binding motif recognize representing residue SARS-CoV SARS-CoV RBD SARS-CoV-2 SARS-CoV-2 RBD Spike protein Substitution mutation the RBD the receptor-binding domain the SARS-CoV-2 the spike protein Vaccine viral spike protein viruses
[DOI] 10.1038/s41423-020-0458-z PMC 바로가기 [Article Type] Article

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

2019 신종 코로나바이러스 수용체 결합 도메인(RBD) 특성 규명: 바이러스 부착 억제제 및 백신으로서의 RBD 단백질 개발에 대한 시사점

Article

Published on 2020-03-192022-09-06
Journal: Cellular and Molecular Immunology
[Category] Communicable Disease, COVID-19, MERS, SARS,

[키워드] 2019 novel coronavirus 2019-nCoV ACE2 ACE2 receptor ACE2-expressing cells acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 angiotensin angiotensin-converting enzyme 2 antibodies binding binding affinity causative agent characterization coronavirus coronavirus disease Coronavirus disease 2019 CoV CoV infection COVID-19 cross-neutralization cross-neutralize SARS-CoV-2 cross-react develop effective Entry inhibitor entry inhibitors enzyme exhibited fusion global public health host cells Human Immunotherapy in viral Infection inhibiting Novel coronavirus outbreak Protein RBD RBD protein Receptor-binding domain receptors respiratory S protein Safe SARS-CoV infection SARS-CoV RBD SARS-CoV RBD-based vaccine SARS-CoV RBD-based vaccines SARS-CoV RBD-induced antisera SARS-CoV RBD-specific antibodies SARS-CoV RBD-specific antibody SARS-CoV-2 SARS-CoV-2 and SARS-CoV infection SARS-CoV-2 RBD SARS-CoV-2 RBD protein SARS-CoV-2 S protein severe acute respiratory syndrome Coronavirus significantly higher specific antibodies Spike protein target the RBD protein the receptor-binding domain Therapeutics Vaccine Vaccines Viral viral attachment inhibitor viral infection viral inhibitor
[DOI] 10.1038/s41423-020-0400-4 PMC 바로가기 [Article Type] Article